U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SALT LAKE CITY, Feb. 18, 2016 -- Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced that it will host a conference call and live webcast to present the 24-month clinical results from a blinded, randomized clinical trial (CASCADE) that compared spinal fusion between its composite silicon nitride fusion devices with a central, cancellous ceramic core, to the industry standard of PEEK spacers filled with bone autograft.
Principal investigator Mark P. Arts, M.D., Ph.D., Neurosurgeon from the Medical Center Haaglanden, The Hague, Netherlands will present the data and Dr. Sonny Bal, Chairman and CEO of Amedica Corporation will discuss its impact on the business. Details related to this call are as follows:
| Date: | Monday March 7, 2016 |
| Time: | 2:00 p.m. Eastern Time |
| Conference ID: | 55371714 |
| Dial-in: | Toll-free (855) 455-6055 |
| International (484) 756-4308 | |
| Webcast: | www.amedica.com |
For those who are not available to listen to the live webcast, the call will be archived on the investor relations section of the Amedica website under Events & Presentations.
About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
Contacts:
Mike Houston
VP, Commercialization
801-839-3534
[email protected]
Robert Haag
IRTH Communications
866-976-4784
[email protected]
